Company Profile

Amarin Corporation plc. is a rapidly growing, innovative pharmaceutical company focused on developing therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa (icosapent ethyl) is Amarin's first FDA-approved drug and is available by prescription. For more information about Vascepa visit www.vascepa.com.

The Company’s first drug, Vascepa (icosapent ethyl) is FDA-approved in the United States for treatment of patients with very high triglyceride levels (TG ≥500 mg/dL). The drug is also available by prescription in Lebanon and the United Arab Emirates. Amarin’s commercial partners are pursuing additional regulatory approvals for Vascepa in Canada, China and the Middle East and Amarin is evaluating potential commercial partnership arrangements for other countries while prioritizing promotion of Vascepa in the United States through Amarin’s sales team. In addition, the company has successfully completed a globally conducted, cardiovascular outcomes study with results which show that Vascepa lowers cardiovascular risk in patients with cardiovascular risk factors which cannot be addressed with cholesterol managing drugs alone. Amarin plans to seek expanded labeling for Vascepa to reflect the results of this outcomes study, called the REDUCE-IT study.

Vascepa (icosapent ethyl) capsules are a single-molecule prescription product consisting of the omega-3 acid commonly known as EPA in ethyl-ester form. Vascepa is not fish oil, but is derived from fish through a stringent and complex FDA-regulated manufacturing process designed to effectively eliminate impurities and isolate and protect the single molecule active ingredient from degradation. Vascepa, known in scientific literature as AMR101, has been designated a new chemical entity by the FDA. Amarin has been issued multiple patents internationally based on the unique clinical profile of Vascepa, including the drug’s ability to lower triglyceride levels in relevant patient populations without raising LDL-cholesterol levels. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

If you are reporting an adverse event or product complaint, please email amarinmi@druginfo.com or call the Amarin Call Center at 1 855 VASCEPA.

» See important safety information about Vascepa
» See full prescribing information for Vascepa

Amarin reported primary results of the successful REDUCE-IT trial concurrent with presentation of these results at the 2018 Scientific Sessions of the American Heart Association on November 10, 2018 in Chicago, Illinois. Results can be found in our press release. Additional references to such results are provided in a slide presentation of such results and in our results investor presentation.

Amarin reported additional results of the successful REDUCE-IT trial at the American College of Cardiology’s 68th Annual Scientific Session. The press release on the data is here. Additional references to these results are provided in this slide presentation.

Amarin is headquartered in Dublin, Ireland. In the U.S., the company's office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").